feedback

Course Director

William K. Oh, MD
William K. Oh, MD

Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
New York, New York

Faculty

Neeraj Agarwal
Neeraj Agarwal

Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

Matthew R. Smith
Matthew R. Smith

Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Evan Y. Yu
Evan Y. Yu, MD

University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, Washington

Accredited by

Purdue University College of Pharmacy

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2020-Mar-18
Expiration Date:2022-Mar-17
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In recent years, the prostate cancer management landscape has become increasingly complex with the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of disease—including nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

At a recent PeerView Live CaseBook program, a panel of experts presented case vignettes to illustrate the best practice management of prostate cancer and how current clinical trends will change patient care. These case-based interludes highlighted evidence from key trials on next-generation androgen-targeting agents; the role of DNA damage-response mutations; biomarker testing and the potential role of innovative targeted therapy; and advances in immunotherapy for prostate cancer. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care.

Upon completion of this activity, participants should be better able to:
  • Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers
  • Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor-, patient-, and treatment-related factors
  • Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum
  • Summarize current evidence and ongoing research with investigational strategies, including molecularly targeted and immune checkpoint inhibitor therapies, for the management of prostate cancer

Target Audience

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of prostate cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 18, 2020 - March 17, 2021
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

All faculty AND staff involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

Chair

William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Deputy Director, The Tisch Cancer Institute
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
New York, New York

William K. Oh, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Sanofi; Sema4; and TeneoBio.

Faculty

Neeraj Agarwal, MD
Professor of Medicine
Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

Neeraj Agarwal, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Astellas Pharma Inc.; Eli Lilly and Company; Exelixis, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Nektar; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Matthew R. Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Matthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Bayer; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; and Pfizer, Inc.
Grant/Research Support from Amgen Inc.; Bayer; Eli Lilly and Company; and Janssen Pharmaceuticals, Inc. (to his institution).
Principal Investigator for a Drug Study for Bayer; Eli Lilly and Company; and Janssen Pharmaceuticals, Inc.

Evan Y. Yu, MD
Professor, Department of Medical Oncology
University of Washington School of Medicine
Medical Director, Clinical Research Support
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Evan Y. Yu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer; Clovis Oncology; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Seattle Genetics, Inc.
Grant/Research Support from Daiichi Sankyo Company, Limited.; Dendreon Pharmaceuticals LLC.; Department of Defense; Merck & Co., Inc.; National Institutes of Health (NIH); Seattle Genetics, Inc.; Taiho Oncology, Inc.; and The National Cancer Institute.
Principal Investigator for a Drug Study for Dendreon Pharmaceuticals LLC.;Merck & Co., Inc.; and Seattle Genetics, Inc.

Medical Director

Carmine Deluca
PVI, PeerView Institute for Medical Education

Carmine Deluca has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members and reviewers, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University College of Pharmacy staff have no relationships to disclose.

Providership, Credit, and Support


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

The Purdue University College of Pharmacy designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Janssen Biotech, Inc., Merck & Co., Inc., Sanofi Genzyme, and Pfizer.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Purdue University College of Pharmacy are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Purdue University College of Pharmacy. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. For approved prescribing information, please consult the manufacturer's product labeling. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our activities. No responsibility is taken for errors or omissions in activities.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.